Jacobi Capital Management’s Theriva Biologics TOVX Stock Holding History

Jacobi Capital Management’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-74	Closed	-$4K	–	419
2022 Q2	$4K	Hold	74	–	–	﹤0.01%	407
2022 Q1	$5K	Hold	74	–	–	﹤0.01%	415
2021 Q4	$5K	Hold	74	–	–	﹤0.01%	426
2021 Q3	$9K	Hold	74	–	–	﹤0.01%	1084
2021 Q2	$11K	Hold	74	–	–	﹤0.01%	1012
2021 Q1	$13K	Buy	+74	New	+$14.6K	﹤0.01%	910
2016 Q4	–	Sell	-1	Closed	-$17K	–	697
2016 Q3	$17K	Hold	1	–	–	0.01%	391
2016 Q2	$18K	Buy	+1	New	+$18.8K	0.01%	368

Other funds holding TOVX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Jacobi Capital Management's TOVX Position: Q3 2022 in Review

Jacobi Capital Management sold out of Theriva Biologics (TOVX) in Q3 2022, closing a stake of 74 shares — an estimated $4K sold.

Jacobi Capital Management first reported a position in TOVX in Q2 2016 and held it in 8 quarters. The position peaked at $18K in Q2 2016. 24 funds tracked by Wall St. Rank hold TOVX as of Q3 2022.

Jacobi Capital Management reported no remaining Theriva Biologics position as of Q3 2022 after selling out during the quarter.
Jacobi Capital Management sold 74 Theriva Biologics shares in Q3 2022, an estimated $4K.
Jacobi Capital Management first reported a position in Theriva Biologics in Q2 2016 and held it in 8 quarters.
Jacobi Capital Management's Theriva Biologics position peaked at $18K in Q2 2016.
24 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2022.

Based on Jacobi Capital Management's 13F filing for Q3 2022, filed 9 Nov 2022.